Topic Menu► ▼ Topic Menu
Broad-Spectrum Antiviral Agents
The global outbreak of COVID-19 is a great threat to humans. There is an urgent need for antiviral therapeutics against SARS-CoV2. A strategy to discover effective antiviral drugs consists of screening existing broad-spectrum antiviral agents for activity against SARS-CoV2. In addition to COVID-19, many other epidemic viral diseases, such as influenza, dengue fever, infections by Zika and Ebola viruses, and western/eastern equine encephalitis, cannot yet be successfully treated.
Developing broad-spectrum antiviral agents to treat epidemic diseases caused by emerging and re-emerging viruses is a priority. To this end, the main approaches are based on targeting viral infectivity and modulating host-defense systems. The antiviral mechanisms of broad-spectrum antiviral candidates should be deeply analyzed in the context of different types of viral diseases. This Special Issue aims to collect studies on broad-spectrum antiviral agents, including existing agents repositioning, herbal components, synthesized compounds, and genetically engineered molecules.
Broad-spectrum antiviral agents hold great potential for controlling viral epidemics in the future.
Dr. Cheng-Wen Lin
Dr. Szu-Hao Kung
- broad-spectrum antiviral agents, BSAA
- host defense
- viral resistance
- small-molecule antiviral
- antiviral analog
- antiviral compounds
- drug repurposing
- antiviral drug development
|Journal Name||Impact Factor||CiteScore||Launched Year||First Decision (median)||APC|
|5.818||6.6||2009||15.6 Days||2600 CHF|
|4.757||3.0||2013||17.4 Days||2200 CHF|
|5.215||4.0||2004||15.6 Days||2200 CHF|
|6.525||6.0||2009||15.9 Days||2600 CHF|
|-||-||2021||16.5 Days||1000 CHF|
Preprints is a platform dedicated to making early versions of research outputs permanently available and citable. MDPI journals allow posting on preprint servers such as Preprints.org prior to publication. For more details about reprints, please visit https://www.preprints.org.